Cheers mate...no hard feelings!!
:t_up::D
Printable View
Craigs (T/P$8.64) note out re Resmed and CareFusion form alliance to compete with FPH in the high flow oxygen mkt which FPH dominates (in USA).
Little immediate risk due to superior patented backed devices; seems FPH have the Gold Standard practically in this area.
I hold FPH and RMD
Yet again another cracker result.
The good gets better and the bad gets worse.
Just as well they reported such a great result, F&P is now only overvalued, instead of extremely overvalued.
Having said this, I do like a good kiwi tech company ;)
Heyye. People can't complain, they were not told.:t_up::t_up:
Well done FPH
$62 m profit H1
$140 m predicted full year
63%GP
9.4% R & D operating revenue
Result highlights for the first half
- 27% growth in net profit after tax to a record NZ$62.0 million.
- 16% increase in interim dividend to 6.7 cps (2015: 5.8 cps).
- 20% growth in operating revenue to a record NZ$381.0 million, 12% growth in constant currency.
- 31% increase in operating profit to NZ$95.2 million, 25% growth in constant currency.
- 18% growth in RAC operating revenue, 11% growth in constant currency.
- Revenue growth for RAC consumables used in NIV, Optiflow and surgical applications of 22% in constant currency, accounting for almost half of RAC consumables revenue.
- 23% growth in OSA operating revenue, 14% growth in constant currency.
- Continued strong performance from OSA masks, 25% revenue growth in constant currency.
- Investment in R&D increased by 14% to NZ$35.8 million, representing 9.4% of operating revenue.
- To have and to hold
- in fitness and bed
- for better for snore
- for ever and bagger:)
Getting very close to $9. Did I miss something?